|
|
|
|
Challenges of pulmonary hypertension make it an ideal candidate for DM
Today's approach to interventions that address chronic disease and conditions is both broader and deeper than ever before. But there is another group of patients who rarely, if ever, directly benefit from these programs. According to Alan Wright, MD, former chief medical officer of TheraCom, these are patients who might use more than $100,000 a year in pharmaceutical spending and/or resources, patients who have a disease that is progressive with no known cure.
|
| |
More>>
|
|
|
|
|
|
Preventing—with the goal of eradicating—sudden cardiac death in children
Sudden cardiac death in a child is an uncommon but devastating occurrence. Using the primary and secondary prevention strategies discussed here, it can also be an avoidable one.
|
| |
More>>
|
|
|
|
|
|
Study diminshes value of beta blockers in treatment of hypertension
Beta blockers, touted for 3 decades as first-line drugs in the treatment of hypertension, are less than optimum in comparison to other antihypertensive drugs and raise the risk of stroke, according to a meta-analysis published online by The Lancet.
|
| |
More>>
|
|
|
|
|
|
How to get your high-risk patients to the new NCEP goals
Now that the optimal LDL-cholesterol level for patients with coronary heart disease or its risk equivalents is substantially below 100 mg/dL, consider aggressive lipid-lowering strategies in this group. With the advent of more powerful statins, combination therapy, and newer nonstatin agents, you can help a significantly greater proportion of your patients attain their lipid goals.
|
| |
More>>
|
|
|
